Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Research & Development (2022 - 2025)

Taysha Gene Therapies' Research & Development history spans 4 years, with the latest figure at $25.7 million for Q3 2025.

  • For Q3 2025, Research & Development rose 72.25% year-over-year to $25.7 million; the TTM value through Sep 2025 reached $76.8 million, up 661.67%, while the annual FY2024 figure was $66.0 million, 1785.74% up from the prior year.
  • Research & Development for Q3 2025 was $25.7 million at Taysha Gene Therapies, up from $20.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $38.2 million in Q1 2022 and bottomed at -$40.6 million in Q4 2023.
  • The 4-year median for Research & Development is $15.6 million (2025), against an average of $14.8 million.
  • The largest annual shift saw Research & Development crashed 419.48% in 2023 before it skyrocketed 137.75% in 2024.
  • A 4-year view of Research & Development shows it stood at $12.7 million in 2022, then plummeted by 419.48% to -$40.6 million in 2023, then surged by 137.75% to $15.3 million in 2024, then skyrocketed by 67.99% to $25.7 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Research & Development are $25.7 million (Q3 2025), $20.1 million (Q2 2025), and $15.6 million (Q1 2025).